Obesity (Silver Spring, Md.)最新文献_第7页

Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials. 减肥、肥胖药物和肥胖相关癌症风险：一项随机对照试验的荟萃分析。

Obesity (Silver Spring, Md.) Pub Date : 2025-11-04 DOI: 10.1002/oby.70054

Chengwen Li, Chu Lin, Xiaoling Cai, Fang Lv, Wenjia Yang, Linong Ji

{"title":"Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.","authors":"Chengwen Li, Chu Lin, Xiaoling Cai, Fang Lv, Wenjia Yang, Linong Ji","doi":"10.1002/oby.70054","DOIUrl":"https://doi.org/10.1002/oby.70054","url":null,"abstract":"Objective: This study aimed to determine whether weight reduction mediated by antiobesity medications (AOMs) contributes to the risk reduction in obesity-associated cancer.Methods: PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and the ClinicalTrials.gov website were systematically searched for randomized controlled trials of AOMs from inception to December 2024. Relative risks were calculated using a random-effects model.Results: The analysis included 25 randomized controlled trials with 40,731 participants. Compared with placebo, AOMs showed no association with the risk of overall obesity-related cancer (RR = 1.03, 95% CI: 0.78 to 1.37) or site-specific cancer. Consistently, every 5 kg weight reduction mediated by AOMs was not associated with the risk of overall obesity-related cancer (RR = 0.97, 95% CI: 0.84 to 1.12) or site-specific cancer. However, subgroup analysis revealed that coagonists (tirzepatide, cotadutide, and cagrilintide) significantly reduced overall obesity-associated cancer risk (RR = 0.43, 95% CI: 0.19 to 0.97), and every 5 kg weight reduction mediated by coagonists was marginally associated with a reduced overall obesity-associated cancer risk (RR = 0.79, 95% CI: 0.62 to 1.00).Conclusions: Weight reduction mediated by current AOMs was not associated with a reduced risk of overall or site-specific obesity-associated cancer in patients with overweight or obesity, while a decreased risk of overall obesity-associated cancer was observed in coagonist users.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145446995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring Effects of a Randomized Online Infant Sleep Intervention on Weight-Related Outcomes Into Toddlerhood. 探索随机在线婴儿睡眠干预对幼儿期体重相关结果的影响。

Obesity (Silver Spring, Md.) Pub Date : 2025-10-26 DOI: 10.1002/oby.70037

Stephanie Anzman-Frasca, Juliana Goldsmith, Amanda B Hassinger, Gregory Wilding, Orfeu M Buxton, Jennifer S Savage

{"title":"Exploring Effects of a Randomized Online Infant Sleep Intervention on Weight-Related Outcomes Into Toddlerhood.","authors":"Stephanie Anzman-Frasca, Juliana Goldsmith, Amanda B Hassinger, Gregory Wilding, Orfeu M Buxton, Jennifer S Savage","doi":"10.1002/oby.70037","DOIUrl":"https://doi.org/10.1002/oby.70037","url":null,"abstract":"Objective: Behavioral sleep interventions may have lasting impacts on sleep and health and serve as a novel obesity prevention strategy. We explored effects of an online infant sleep intervention on sleep, weight status, and weight-related behaviors (e.g., diet) into toddlerhood.Methods: First-time parents or legal guardians ≥ 18 years old were recruited when their infant was < 6 weeks old and randomized (block size 2, 1:1 allocation ratio) to a sleep intervention (n = 36) or baby care control group (n = 38). The intervention was delivered weekly via private online groups when infants were 2-4 months old. Participants completed surveys at baseline (infant age 6 weeks), midpoint (3 months), post-intervention (4 months), and infant follow-up (7 months). Participants also completed a toddler follow-up survey (mean age = 20.7 months; n = 67) assessing behaviors and weight/length.Results: By toddlerhood, the intervention group slept longer (12.99 ± 2.03 vs. 11.94 ± 2.06 h per day, p = 0.049) and had lower weight-for-length z-scores (0.62 ± 1.34 vs. 1.33 ± 1.35, p = 0.04) than controls.Conclusions: Results support early sleep interventions as a novel and promising approach to childhood obesity prevention and demonstrate the feasibility of online intervention delivery. Future research should further examine mechanisms and confirm findings using objective weight status measures.Trial registration: ClinicalTrials.gov identifier: NCT05322174.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145373513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GLP-1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation. GLP-1受体激动剂和老年2型糖尿病患者的物质使用障碍：一项目标试验模拟

Obesity (Silver Spring, Md.) Pub Date : 2025-09-15 DOI: 10.1002/oby.70024

Hao Dai, Rotana M Radwan, Grant D Scheiffele, Huilin Tang, Amy Sheer, Hsin-Yueh Lin, Pengyue Zhang, Darlene Adirika, Kate Luong, Jiang Bian, Jingchuan Guo

{"title":"GLP-1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation.","authors":"Hao Dai, Rotana M Radwan, Grant D Scheiffele, Huilin Tang, Amy Sheer, Hsin-Yueh Lin, Pengyue Zhang, Darlene Adirika, Kate Luong, Jiang Bian, Jingchuan Guo","doi":"10.1002/oby.70024","DOIUrl":"10.1002/oby.70024","url":null,"abstract":"Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for type 2 diabetes (T2D) and obesity, may modulate reward pathways and reduce substance-related behaviors. This study assessed the association between GLP-1RA use and substance use-related hospitalization in older adults with coexisting T2D and substance use disorders (SUD).Methods: A retrospective cohort study using 2016-2020 Medicare data compared GLP-1RA initiators with new users of SGLT2 inhibitors (SGLT2is) or DPP-4 inhibitors (DPP4is) among adults aged ≥ 65. The primary outcome was hospitalization for any SUD; secondary outcomes included hospitalizations for alcohol use disorder (AUD) and opioid use disorder (OUD). Propensity score 1:1 matching and Cox proportional hazards models were used under an intention-to-treat approach.Results: In the GLP-1RA versus DPP4i cohort (n = 4920), GLP-1RA users had a lower risk of SUD hospitalization (HR 0.76; 95% CI, 0.67-0.86) and OUD hospitalization (HR 0.64; 95% CI, 0.43-0.96), with a nonsignificant trend for AUD (HR 0.76; 95% CI, 0.53-1.08). No significant differences were observed compared to SGLT2is (n = 4620).Conclusions: Among older adults with T2D, GLP-1RA use was associated with reduced SUD-related hospitalization versus DPP4i use, suggesting potential repurposing for SUD management.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12701773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of Glucagon-Like Peptide-1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes. 胰高血糖素样肽-1受体激动剂与老年2型糖尿病患者癌症风险的关系

Obesity (Silver Spring, Md.) Pub Date : 2025-08-21 DOI: 10.1002/oby.24366

Ying Lu, Hao Dai, Huilin Tang, William T Donahoo, Thomas J George, Ramon C Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D Licht, John M Allen, Kelvin P Lee, Jingchuan Guo, Jiang Bian

{"title":"Association of Glucagon-Like Peptide-1 Receptor Agonists With Cancer Risk in Older Adults With Type 2 Diabetes.","authors":"Ying Lu, Hao Dai, Huilin Tang, William T Donahoo, Thomas J George, Ramon C Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D Licht, John M Allen, Kelvin P Lee, Jingchuan Guo, Jiang Bian","doi":"10.1002/oby.24366","DOIUrl":"10.1002/oby.24366","url":null,"abstract":"Objective: The real-world evidence on the association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cancer risk remains limited and mixed.Methods: In 2013-2020 national Medicare claims data, we included cancer-naïve patients with type 2 diabetes (T2D). We identified those who initiated GLP-1 RA, sodium-glucose cotransporter 2 inhibitor (SGLT2i), or dipeptidyl peptidase 4 inhibitor (DPP4i) and conducted 1:1 propensity score matching for confounding adjustment. Cox proportional hazards models were used to estimate hazard ratios (HR) of nine obesity-associated cancers (thyroid, pancreatic, bladder, colorectal, lung, kidney, breast, endometrial, and prostate cancer).Results: In the matched GLP-1RA versus SGLT2i cohort (n = 21,362 pairs), GLP-1RA users had similar overall cancer risk with SGLT2i users (HR, 1.03 [95% CI, 0.95-1.12]), but GLP-1RAs were associated with an increased kidney cancer risk (HR, 1.43 [1.06-1.92]). In the matched GLP-1RA versus DPP4i cohort (n = 20,962 pairs), the GLP-1RA versus DPP4i comparison showed no significant difference in overall cancer risk (HR, 0.96 [0.89-1.04]) but revealed a significantly elevated endometrial cancer risk (HR, 1.55 [1.01-2.37]).Conclusion: GLP-1RAs might be associated with an increased risk of certain cancer types. Future studies are needed to validate the potential tumorigenic risk associated with GLP1-RAs.","PeriodicalId":94163,"journal":{"name":"Obesity (Silver Spring, Md.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12906048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neighborhood health-promoting resources and obesity risk (the Multi-Ethnic Study of Atherosclerosis) 社区健康促进资源与肥胖风险(动脉粥样硬化多民族研究)

Obesity (Silver Spring, Md.) Pub Date : 2012-07-04 DOI: 10.1038/oby.2012.91

Amy H. Auchincloss, M. Mujahid, Mingwu Shen, E. Michos, M. Whitt-Glover, A. D. Diez Roux

引用次数: 1

Comparison of Body Adiposity Index (BAI) and Body Mass Index (BMI) with Estimations of % Body Fat in Clinically Severe Obese Women 临床重度肥胖妇女体脂指数(BAI)、体质量指数(BMI)与体脂百分比估算的比较

Obesity (Silver Spring, Md.) Pub Date : 2012-07-04 DOI: 10.1038/oby.2012.187

A. Geliebter, D. Atalayer, L. Flancbaum, C. Gibson

引用次数: 34

Family-Based Hip-Hop to Health: Outcome Results 以家庭为基础的Hip-Hop健康:结果

Obesity (Silver Spring, Md.) Pub Date : 2012-06-15 DOI: 10.1038/oby.2012.136

M. Fitzgibbon, M. Stolley, L. Schiffer, A. Kong, C. Braunschweig, S. Gomez-Perez, A. Odoms-Young, L. V. Van Horn, K. Christoffel, A. Dyer

引用次数: 3